ST三圣(002742) - 2020 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2020 was ¥2,549,509,857.65, a decrease of 19.83% compared to ¥3,180,117,049.92 in 2019[16] - The net profit attributable to shareholders for 2020 was ¥73,436,772.60, down 41.17% from ¥124,835,098.47 in 2019[16] - The net profit after deducting non-recurring gains and losses was ¥51,631,697.38, a decline of 55.40% from ¥115,756,564.29 in 2019[16] - The basic earnings per share for 2020 was ¥0.1700, a decrease of 41.18% compared to ¥0.2890 in 2019[16] - The total assets at the end of 2020 were ¥4,877,608,615.06, a decrease of 2.94% from ¥5,025,238,817.68 at the end of 2019[16] - The net assets attributable to shareholders at the end of 2020 were ¥1,515,966,359.02, down 2.49% from ¥1,554,689,593.61 at the end of 2019[16] - The net cash flow from operating activities was ¥140,899,447.36, a decrease of 8.90% from ¥154,662,019.19 in 2019[16] - The weighted average return on net assets for 2020 was 4.79%, down from 8.18% in 2019[16] Revenue Segmentation - The construction materials segment generated revenue of approximately ¥1.85 billion, down 24.56% year-on-year, primarily due to market instability and increased environmental pressures[41] - The pharmaceutical manufacturing segment achieved revenue of approximately ¥664.92 million, with a year-on-year decline of 4.67%, indicating a gradual increase in its share of the company's overall business[42] - The construction materials and chemicals segment accounted for 72.54% of total revenue, with a revenue of approximately ¥1.85 billion, down 24.56% year-over-year[48] - The pharmaceutical segment generated approximately ¥664.92 million, representing 26.08% of total revenue, with a decline of 4.67% from the previous year[49] Operational Highlights - The company plans not to distribute cash dividends or issue bonus shares for the year[5] - The company has faced risks related to its ongoing operations, which are detailed in the report[4] - The company reported non-operating income of approximately ¥21.81 million for 2020, compared to ¥9.08 million in 2019, indicating an increase of 140.5% year-over-year[22] - The company achieved a year-on-year increase of 32.07% in construction projects under construction, primarily due to the expansion of the green circular building materials industry base project in Yubei District[31] Market Position and Strategy - The construction materials industry in China is closely tied to macroeconomic conditions, with significant reliance on fixed asset investment and infrastructure spending, presenting growth opportunities for the company[28] - The company operates primarily in the Chongqing region for its construction materials segment, benefiting from local market conditions and infrastructure investments[28] - The company has established a reliable supply chain system, enhancing its procurement capabilities through various models such as tender procurement and long-term strategic cooperation[27] - The company has a diversified and international development strategy, which effectively mitigates operational risks associated with economic cycles[33] Research and Development - The company has established a research center for concrete additives, focusing on developing high-performance products tailored to customer needs[34] - The company has established a comprehensive drug research and development system, focusing on antibiotics, digestive, respiratory, endocrine, and cardiovascular drugs[35] - The company has made significant investments in overseas projects, with initial results from these investments becoming apparent as international strategies are implemented[30] - The company has a strong technical advantage, supported by a robust research and development framework for concrete additives and pharmaceuticals[33] Environmental and Regulatory Compliance - The company emphasizes sustainable development while considering investor returns, adhering to relevant laws and regulations regarding profit distribution[98] - The company strictly adheres to various environmental protection laws and standards, including the Air Pollution Prevention and Control Law and the Water Pollution Prevention and Control Law[140] - The company has implemented a comprehensive pollution control system, including bag filters and electrostatic precipitators at each discharge outlet, ensuring compliance with environmental standards[145] - The company has established an automatic online monitoring system for emissions, managed by a qualified third party to ensure compliance[145] Shareholder and Governance - The company maintained shareholder rights by legally convening shareholder meetings[136] - The company has not engaged in any mergers or acquisitions during the reporting period[165] - The management team consists of experienced professionals with backgrounds in finance and pharmaceuticals[174][175] - The company has not reported any new product developments or technological advancements in the current reporting period[165] Employee and Management Structure - The total number of employees in the company is 3,085, with 2,053 in production, 126 in sales, 354 in technical roles, 60 in finance, and 492 in administration[183] - The company has established a training plan to enhance employee skills and management capabilities, focusing on various aspects including occupational skills and safety management[186] - The company has a competitive salary and benefits system, with employee compensation consisting of basic and performance-based wages[185] - The company’s board of directors and senior management have not been granted any stock incentives during the reporting period[182]